No Detail Found!

Current and emerging trends in the management of pyoderma gangrenosum: a literature review

Author(s)
Sobia Wali Muhammad Liaquat University of Medical and Health Sciences,Jamshoro-,Pakistan
Nadia Hassan Dow University of Health Sciences,Karachi-,Pakistan
Samra Khan International Center for Chemical and Biological Sciences, University of Karachi-,,Pakistan
Atia Gohar Dow Institute of Biology and Advance Research,Karachi-,Pakistan
Abstract
The first description of Pyoderma gangrenosum (PG) was made about a century ago. It is difficult to understand the aetiology, pathophysiology, and therapy of PG. This disease is believed to be caused by a systemic inflammatory response to neutrophil chemotaxis and faulty innate immune system control. Nearly fifty percent of the cases have underlying systemic symptoms. Significant improvements in PG management have been made over the years. The main goals of treatment are to reduce inflammation and speed up the healing of the PG wound. Even though the most recent medicines show promise, they are found on isolated case reports. The majority of patients are typically managed with topical treatment and local wound care, while resistant cases necessitate immunosuppressive medications. More progress can be made with improvements in technology in deciphering this complex disease and getting a greater understanding of the condition. The present standard therapies for refractory PG are not well supported by studies. In refractory PG, corticosteroids and cyclosporine have historically been administered. Tumour necrosis factor inhibitors are becoming a viable option; nonetheless, this requires careful research and upkeep. This review intended to describe the current trends in managing the PG. Several next-generation treatment options including the conventional therapies introduced to treat PG. We encompass the advantages and disadvantages of new treatments for PG.
Publication Details
Page(s) 774-784
Published Journal: Journal of Ayub Medical College, Volume: 35, Issue: 4(S), Year: 2023

Request the full text from PASTIC

Keywords
Pyoderma gangrenosum, Refractory, Immunosuppressive, Systemic management
References
George C,Deroide F,Rustin M. .2019 .Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med, 19(3) : 224-8.
Wollina U. Pyoderma .2007 .. Orphanet J Rare Dis, 2 : 19.
Butcher M. .2005 .Pyoderma gangrenosum: a diagnosis not to be missed. WOUNDS UK, 1(3) : 84.
Fulbright RK,Wolf JE,Tschen JA .1985 .Residents' corner: pyoderma gangrenosum at surgery sites. J Dermatol Surg Oncol, 11(9) : 883-6.
Adachi Y,Kindzelskii AL,Cookingham G,Shaya S,Moore EC,Todd RF .1998 .Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol, 111(2) : 259-68.
van den Berg TK,Kuijpers TW .2013 .Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am, 27(1) : 101-16.
Su WP,Davis MD,Weenig RH,Powell FC,Perry HO .2004 .Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol, 43(11) : 790-800.
Menter A,Gottlieb A,Feldman SR,Van Voorhees AS,Leonardi CL,Gordon KB .2008 .Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol, 58(5) : 826-50.
Sandborn WJ,Targan SR .2002 .Biologic therapy of inflammatory bowel disease. Gastroenterology, 122(6) : 1592-1608.
Chow RK,Ho VC .1996 .Treatment of pyoderma gangrenosum. J Am Acad Dermatol, 34(6) : 1047-60.
Wang AS,Armstrong EJ,Armstrong AW .2013 .Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg, 206(3) : 410-7.
Hughes AP,Jackson JM,Callen JP. .2000 .Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA, 284(12) : 1546-8.
Goldstein F,Krain R,Thornton JJ .1985 .Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol, 7(6) : 499-501.
Jennings J .1983 .Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol, 9(4) : 575-80.
Homey B,Assmann T,Vohr HW,Ulrich P,Lauerma AI,Ruzicka T .1998 .Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol, 160(11) : 5331-40.
Schuppe HC,Homey B,Assmann T,Martens R,Ruzicka T. .1998 .Topical tacrolimus for pyoderma gangrenosum. Lancet, 351(9105) : 832.
Reich K,Vente C .1998 .Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol, 139(4) : 755-7.
Sehgal VN,Srivastava G,Dogra S. .2008 .Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions. dosages, and side effects: part I. Skinmed, 7(1) : 27-30.
Tamir A,Landau M,Brenner S. .1996 .Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology, 192(3) : 252-4.
Saffouri B,Hom BM,Mertesdorf JM,Gardiner JF JM .1984 .Treatment of pyoderma gangrenosum with disodium cromoglycate. Dig Dis Sci, 29 : 183-5.
De Cock K,Thorne M. .1980 .The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol, 102(2) : 231-3.
Sanders C,Hulsmans R. .1993 .Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis, 51(4) : 262-4.
Ahronowitz I,Harp J,Shinkai K. .2012 .Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol, 13 : 191-211.
Tsele E,Yu R,Chu A .1992 .Pyoderma gangrenosum-response to topical nitrogen mustard. Clin Exp Dermatol, 17(6) : 437-40.
Nguyen L,Weiner J .1977 .Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis, 19(6) : 842-4.
Vereecken P,Wautrecht JC,De Dobbeleer G,Heenen M. .1997 .A case of pyoderma gangrenosum stabilized with lymecycline, topical benzoyl peroxide and treated by autograft. Dermatology, 195(1) : 50-1.
.2004 .Nicotine effects on skin: are they positive or negative?. Exp Dermatol, 13(11) : 665-70.
Wolf R,Ruocco V .1998 .Nicotine for pyoderma gangrenosum. Arch Dermatol, 134(9) : 1071-2.
Heldin CH,Westermark B. Mechanism .1999 .of action and in vivo role of platelet-derived growth factor. Physiol Rev, 79(4) : 1283-316.
Braun-Falco M,Kovnerystyy O,Lohse P,Ruzicka T. .2012 .Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol, 66(3) : 409-15.
Morrissey PJ,Grabstein KH,Reed SG,Conlon PJ .1989 .Granulocyte/macrophage colony stimulating factor. A potent activation signal for mature macrophages and monocytes. Int Arch Allergy Immunol, 88(1-2) : 40-5.
White LE,Villa MT,Petronic-Rosic V,Jiang J,Medenica MM .2006 .Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed, 5(2) : 96-8.
Callen JP .1998 .Pyoderma gangrenosum. Lancet, 351(9102) : 581-5.
Lebbe C,Moulonguet-Michau I,Perrin P,Blanc F,Frja J,Civatte J .1992 .Steroid-responsive pyoderma gangrenosum with vulvar and pulmonary involvement. J Am Acad Dermatol, 27(4) : 623-5.
Gupta AK,Brown MD,Ellis CN,Rocher LL,Fisher GJ,Baadsgaard O .1989 .Cyclosporine in dermatology. J Am Acad Dermatol, 21(6) : 1245-56.
Matis WL,Ellis CN,Griffiths CE,Lazarus GS .1992 .Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol, 128(8) : 1060-4.
Gasior-Chrzan B,Stenvold S,Falk E .1995 .Treatment of pyoderma gangrenosum with cyclosporine. J Eur Acad Dermatol Venereol, 5 : S162.
Ahmed AR,Hombal SM .1984 .Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol, 11(6) : 1115-26.
Newell LM,Malkinson FD .1983 .Pyoderma gangrenosum: response to cyclophosphamide therapy. Arch Dermatol, 119(6) : 495-7.
Crawford SE,Sherman R,Favara B .1967 .Pyoderma gangrenosum with response to cyclophosphamide therapy. J Pediatr, 71(2) : 255-8.
Cronstein BN .1996 .Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum, 39(12) : 1951-60.
Teitel .1996 .A. Treatment of pyoderma gangrenosum with methotrexate. Cutis, 57(5) : 326-8.
Brown R,Lay L,Graham D. .1993 .Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg, 18(1) : 119-21.
Perri III AJ,Hsu S. .2003 .A review of thalidomide's history and current dermatological applications. Dermatol Online J, 9(3) : 5.
Federman GL,Federman DG .2000 .Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc, 75(8) : 842-4.
Thomsen K,Rothenborg HW .1979 .Clofazimine in the treatment of pyoderma gangrenosum. Arch Dermatol, 115(7) : 851-2.
Michaëlsson G,Molin L,Ohmann S,Gip L,Lindström B,Skogh M .1976 .Clofazimine: a new agent for the treatment of pyoderma gangrenosum. Arch Dermatol, 112(3) : 344-9.
Abu-Elmagd K,Van Thiel DH,Jegasothy BV,Jacobs JC,Carroll P,Rodriquez-Rilo H .1993 .Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med, 119(7) : 595-8.
Weichert G,Sauder DN .1998 .Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. J Am Acad Dermatol, 39(4) : 648-50.
Bhat RM .2004 .Management of pyoderma gangrenosum-An update. Indian J Dermatol Venereol Leprol, 70(6) : 329-35.
Breathnach S,Wells G,Valdimarsson H .1981 .Idiopathic pyoderma gangrenosum and impaired lymphocyte function: failure of azathioprine and corticosteroid therapy. Br J Dermatol, 104(5) : 567.
Davies M,Piper S M .1981 .Pyoderma gangrenosum: successful treatment with minocycline. Clin Exp Dermatol, 6(2) : 219-23.
Burruss JB,Farmer ER,Callen JP .1996 .Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol, 35(5) : 720-4.
Gelernt I,Kreel I. .1976 .Pyoderma gangrenosum in ulcerative colitis: prevention of the gangrenous component. Mt Sinai J Med, 43(4) : 467-70.
Cliff S,Holden CA,Thomas PR,Marsden RA,Harland CC .1999 .Split skin grafts in the treatment of pyoderma gangrenosum: a report of four cases. Dermatol Surg, 25(4) : 299-302.
Fonder MA,Lazarus GS,Cowan DA,Aronson-Cook B,Kohli AR,Mamelak AJ .2008 .Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol, 58(2) : 185-206.
Gottrup F,Karlsmark T. .2005 .Leg ulcers: uncommon presentations. Clin Dermatol, 23(6) : 601-11.
Le Cleach L,Moguelet P,Perrin P,Chosidow O .2011 .Is topical monotherapy effective for localized pyoderma gangrenosum?. Arch Dermatol, 147(1) : 101-3.
Fonseka HF,Ekanayake SM,Dissanayake M. .2010 .Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study. Int Wound J, 7(6) : 519-23.
Bellini V,Simonetti S,Lisi P. .2008 .Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol, 22(1) : 113-5.
Piccirillo A,Ricciuti F .2006 .Topical tacrolimus for pyoderma gangrenosum: another report. J Dermatol, 33(3) : 232.
Chiba T,Kiehl P,Breuer C,Kapp A,Werfel T. .2005 .Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol, 32(3) : 199-203.
Fraccalvieri M,Fierro MT,Salomone M,Fava P,Zingarelli EM,Cavaliere G .2014 .Gauze‐based negative pressure wound therapy: a valid method to manage pyoderma gangrenosum. Int Wound J, 11(2) : 164-8.
Chriba M,Skellett A,Levell N. .2010 .Beclometasone inhaler used to treat pyoderma gangrenosum. Clin Exp Dermatol, 35(3) : 337-8.
Kluger N. .2012 .Can snus (Swedish moist snuff) be used as a treatment of Pyoderma gangrenosum?. Med Hypotheses, 78(5) : 619-20.
Rutgeerts P,Vermeire S .2009 .Biological therapies for inflammatory bowel diseases. Gastroenterology, 136(4) : 1182-97.
Reguiai Z,Grange F. .2007 .The role of anti-tumor necrosis factor-α therapy in pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol, 8 : 67-77.
Gisondi P,Girolomoni G .2007 .Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev, 6(8) : 515-9.
Brooklyn TN,Dunnill MG,Shetty A,Bowden JJ,Williams JD,Griffiths CE .2006 .Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 55(4) : 505-9.
Regueiro M,Valentine J,Plevy S,Fleisher MR,Lichtenstein GR .2003 .Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol, 98(8) : 1821-6.
Traczewski P,Rudnicka L .2008 .Adalimumab in dermatology. Br J Clin Pharmacol, 66(5) : 618-25.
Fonder MA,Cummins DL,Ehst BD,Anhalt GJ,Meyerle JH .2006 .Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds, 5 : e8.
Heffernan MP,Anadkat MJ,Smith DI .2007 .Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol, 143(3) : 306-8.
Goffe B,Cather JC .2003 .Etanercept: an overview. J Am Acad Dermatol, 49(2) : 105-11.
Gardam MA,Keystone EC,Menzies R,Manners S,Skamene E,Long R .2003 .Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 3(3) : 148-55.
Pastor N,Betlloch I,Pascual JC,Blanes M,Bañuls J,Silvestre JF .2006 .Pyoderma gangrenosum treated with anti‐TNF alpha therapy (etanercept. Clin Exp Dermatol, 31(1) : 152-3.
Goldenberg G,Jorizzo JL .2005 .Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat, 16(5-6) : 347-9.
Charles CA,Leon A,Banta MR,Kirsner RS .2007 .Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol, 46(10) : 1095-9.
Ruocco E,Sangiuliano S,Gravina AG,Miranda A,Nicoletti G .2009 .Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol, 23(9) : 1008-17.
Graves JE,Nunley K,Heffernan MP .2007 .Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol, 56(1) : e55-79.
Foss CE,Clark AR,Inabinet R,Camacho F,Jorizzo JL .2008 .An open‐label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol, 22(8) : 943-9.
Miller J,Yentzer BA,Clark A,Jorizzo JL,Feldman SR .2010 .Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol, 62(4) : 646-54.
Wollina U .2011 .Pyoderma gangraenosum. Curr Opin Rheumatol, 23(1) : 50-6.
Lorincz M,Kleszky M,Szalóki T .2010 .Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis. Orv Hetil, 151(4) : 144-7.
Guenova E,Teske A,Fehrenbacher B,Hoerber S,Adamczyk A,Schaller M .2011 .Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol, 147(10) : 1203-5.
Allison AC,Eugui EM .2000 .Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2- 3) : 85-118.
Eaton PA,Callen JP .2009 .Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol, 145(7) : 781-5.
Cummins DL,Anhalt GJ,Monahan T,Meyerle JH .2007 .Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol, 157(6) : 1235-9.
Qiu L,Zheng S,Wu J,Xiao T,Chen HD .2012 .Refractory disseminated pyoderma gangrenosum, with dependence on corticosteroids, responding to potassium iodide. Eur J Dermatol, 22(3) : 426-7.
Saniabadi AR,Hanai H,Takeuchi K,Umemura K,Nakashima M,Adachi T .2003 .Adacolumn, an Adsorptive Carrier Based Granulocyte and Monocyte Apheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes. Ther Apher Dial, 7(1) : 48-59.
Okuma K,Mitsuishi K,Hasegawa T,Tsuchihashi H,Ogawa H,Ikeda S H .2007 .A case report of steroid and immunosuppressantresistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial, 11(5) : 387-90.
de Imus G,Golomb C,Wilkel C,Tsoukas M,Nowak M,Falanga V .2001 .Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol, 44(1) : 61-6.
Duchini G,Itin P,Arnold A. .2011 .A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. Adv Skin Wound Care, 24(5) : 217-20.
Altunay I,Kucukunal A,Sarikaya S .2014 .A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum. Int Wound J, 11(4) : 350-3.
Li LF .2000 .Treatment of pyoderma gangrenosum with oral Tripterygium wilfordii multiglycoside. J Dermatol, 27(7) : 478-81.
0

Citations

0

Downloads

62

Views